Liraglutide

Adjunct to diet/exercise for type 2 diabetes glycemic control in adults and patients at least ten years old. Reduction of major adverse cardiovascular events is labeled in adults with type 2 diabetes and established cardiovascular disease; not a pediatric or universal weight-loss benefit. Coadministration with another liraglutide product is not recommended.

With reduced-calorie diet/activity for long-term weight reduction/maintenance: the current indication describes adults and pediatric patients at least twelve years old with weight over 60 kg and obesity, and adults with overweight plus a weight-related comorbidity. Pediatric section specifies an initial BMI corresponding to adult BMI at least 30 by international cut-offs; use pediatric classification, not a fixed adult BMI for every child. Pediatric type 2 diabetes safety/effectiveness for Saxenda is unestablished. Do not combine with another liraglutide product or another GLP-1 agonist.

Adults: maintenance 3 mg; lower doses are titration only. May delay an increase about one extra week for intolerance; stop if unable to tolerate 3 mg. At sixteen weeks after initiation, stop if loss is under 4% of baseline weight. Pediatric: may lower to prior escalation step and take up to eight weeks to escalate; maintenance 3 mg or 2.4 mg if 3 mg intolerable, stop if 2.4 mg intolerable. After twelve weeks on maintenance, stop if BMI reduction is under 1% from baseline.

Inject SC abdomen, thigh or upper arm once daily independent of meals; rotate sites, inspect for clear/colorless particle-free solution and never share pens. Do not mix with insulin; Victoza and insulin may use the same region but not adjacent injections. Missed dose: resume next scheduled dose without extra/increased dosing. If more than three days since last dose, restart 0.6 mg; Victoza subsequent titration is prescriber-directed, Saxenda follows escalation. Verify pen dose markings; no click-count or combination-insulin conversion is supplied.

Both selected current labels contraindicate personal/family MTC history, MEN2 and serious liraglutide/ingredient hypersensitivity. Current Saxenda section four does not list pregnancy as a formal contraindication, but section eight specifically directs discontinuation when pregnancy is recognized because weight loss offers no pregnancy benefit.

Both labels warn of dose/duration-related thyroid C-cell tumors in rodents; human relevance and causality are unknown. MTC/MEN2 history excludes treatment. Counsel neck mass, swallowing/breathing difficulty or persistent hoarseness; routine calcitonin/thyroid ultrasound screening has uncertain value and can trigger unnecessary procedures.

Common effects include nausea, diarrhea, vomiting, constipation, dyspepsia and appetite reduction. Saxenda also reports headache, injection-site reactions, fatigue/dizziness and hypoglycemia. Serious/postmarketing reports include pancreatitis, biliary disease, dehydration/AKI, allergy, obstruction/ileus/severe constipation and aspiration; reporting cannot establish reliable incidence or causality for every event.

Consider reducing insulin or a sulfonylurea/other secretagogue with monitoring to lower hypoglycemia risk. Do not automatically reduce every diabetes medicine by a fixed percentage. Avoid duplicate liraglutide; Saxenda also advises against any other GLP-1 agonist. Insulin-containing fixed combinations have separate instructions.

Gastric emptying is delayed and can affect oral medicine absorption. Tested medicines generally lacked clinically meaningful overall absorption changes, but monitor consequences in the actual combination. Procedure-related aspiration planning is individualized, not a drug-interaction proof that fasting alone removes risk.

Animal studies found developmental harm and human risk data are limited. Victoza uses benefit-versus-fetal-risk language for diabetes; poor maternal diabetes control also harms pregnancy. Saxenda directs stopping once pregnancy is recognized because weight loss offers no benefit and may harm the fetus. Human milk/infant/milk-production data are absent for both; animal milk transfer exists. Review maternal need and feeding benefits/risks.

Victoza diabetes approval starts at ten; Saxenda pediatric obesity starts at twelve with weight over 60 kg and pediatric BMI criteria. Saxenda pediatric type 2 diabetes use is unestablished. Monitor pediatric hypoglycemia; older-adult trials showed no overall age-only difference but individual sensitivity/volume-depletion risks remain.

Victoza recommends no renal adjustment, with limited ESRD experience; it recommends no hepatic adjustment but cautious use because experience is limited. Saxenda has limited renal experience including ESRD and limited hepatic experience requiring caution, without a numeric table. Both require monitoring during dehydration; absence of a routine adjustment is not absence of AKI risk.

Liraglutide stimulates insulin release and suppresses glucagon in a glucose-dependent manner while delaying gastric emptying. Weight reduction involves reduced calorie intake/appetite regulation; it does not increase twenty-four-hour energy expenditure in the selected Saxenda pharmacodynamic description.

Fatty-acid modification, self-association and high protein binding prolong activity; SC half-life is around thirteen hours and protein binding exceeds 98%. Peaks occur roughly eight to twelve hours depending on studied product/population. It undergoes large-protein-like metabolism without one organ as the main elimination route; no intact liraglutide was detected in urine/feces in the radiolabel study.

Follow glucose/HbA1c for diabetes and weight/BMI response for Saxenda stopping rules; monitor resting pulse with Saxenda and renal function with volume-depleting symptoms. Recognize hypoglycemia and report pancreatitis/biliary symptoms, neck symptoms or allergy. Inform anesthesia teams and discuss pregnancy. Use new needles, remove after injection, never share and follow trained device technique rather than counting clicks.

Seek medical/Poison Control or toxicology advice; overdose can cause severe nausea/vomiting and hypoglycemia. Supportive management follows clinical findings. No home antidote, safe excess dose or universal treatment threshold is supplied.

Victoza

18 mg / 3 mL pen; delivers 0.6, 1.2 or 1.8 mg

Victoza example

Two pens · NDC 0169-4060-12

Saxenda

18 mg / 3 mL pen; delivers 0.6, 1.2, 1.8, 2.4 or 3 mg

Saxenda example

Five pens · NDC 0169-2800-15

Selected single-agent SC pens contain 6 mg/mL clear/colorless solution. Their selectable dose ranges and purposes differ despite matching concentration. Generics, compounded preparations and degludec/liraglutide fixed combinations require their own identification/regimen and are not reviewed.

Before first use, refrigerate at 2–8°C away from the cooling element. Never freeze/use previously frozen solution. After first use, either refrigerate or store at 15–30°C for thirty days, then discard residual product. Cap when unused, protect from excessive heat/sunlight, remove/discard needles after dosing and store without a needle attached.